Addressing Concerns for Successful Implementation of National Health Insurance in South Africa

By HEOR Staff Writer

May 10, 2023

Addressing Concerns for Successful Implementation of National Health Insurance in South Africa: Perspectives from Policymakers and the Role of Pharmacists in Primary Healthcare Re-engineering

In this study, policymakers in South Africa were interviewed to gain insights into their perspectives on the implementation of National Health Insurance (NHI) and the role of pharmacists in primary healthcare (PHC) re-engineering.

The study identified several concerns that could compromise the efficient functionality of NHI and attaining universal healthcare (UHC). These concerns included the need for appropriate governance and regulatory mechanisms, the complexity of issues experienced at local levels of care, the involvement of private healthcare providers and the lack of reimbursement mechanisms, the need for stakeholder engagement and communication, and the underutilization of pharmacists in the healthcare system. The study highlights the importance of proactive and positive engagement with key role-players to address these concerns and ensure the successful implementation of NHI and PHC re-engineering in South Africa.

Reference url

Recent Posts

Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...
pharmaceutical innovation ROI
Shifting Perspectives on Pharmaceutical Innovation ROI as Socioeconomic Investment

By João L. Carapinha

June 24, 2026

Pharmaceutical innovation ROI is shifting from a narrow budget metric to a powerful indicator of societal return. Between 2014 and 2024, a 3.1-year rise in utilization-weighted mean drug vintage across 29 European countries prevented 1.83 million years of life lost before age 85 and saved 20.9 mi...
pharmaceutical innovation benefits
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe

By João L. Carapinha

June 23, 2026

Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...